Critical care of HIV infected patients in the highly active antiretroviral therapy era

Minerva Anestesiologica

Volumn 73, Issue 12, 2007, Pages 635-645

  Corona, A ^a   Raimondi, F ^a  

^a UNIVERSITY OF MILAN   (Italy)

Author keywords

Antiretroviral therapy; Highly active; HIV infections; Intensive Care Units

Indexed keywords

ABACAVIR; AMIODARONE; AMPRENAVIR; ANTIRETROVIRUS AGENT; ATAZANAVIR; DELAVIRDINE; DIDANOSINE; DILTIAZEM; EFAVIRENZ; ERGOTAMINE; INDINAVIR; LOPINAVIR PLUS RITONAVIR; METHADONE; METRONIDAZOLE; MIDAZOLAM; NELFINAVIR; NEVIRAPINE; NIFEDIPINE; NUCLEOSIDE ANALOG; PETHIDINE; PROTEINASE INHIBITOR; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; SAQUINAVIR; SILDENAFIL; STAVUDINE; TENOFOVIR; UNINDEXED DRUG; ZALCITABINE; ZIDOVUDINE;

ACUTE KIDNEY TUBULE NECROSIS; ATHEROSCLEROSIS; BACTERIAL INFECTION; BONE MARROW SUPPRESSION; CARDIOVASCULAR DISEASE; CRITICAL ILLNESS; DIABETES MELLITUS; DRUG HYPERSENSITIVITY; DRUG POTENTIATION; GLUCOSE INTOLERANCE; HEART DISEASE; HEART INFARCTION; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HOSPITAL ADMISSION; HOSPITAL DISCHARGE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERCHOLESTEROLEMIA; IMMUNE RECONSTITUTION INFLAMMATORY SYNDROME; INTENSIVE CARE; INTENSIVE CARE UNIT; INTERSTITIAL NEPHRITIS; ITALY; KIDNEY DISEASE; LACTIC ACIDOSIS; LIVER DISEASE; LIVER TOXICITY; LUNG DISEASE; MORTALITY; MYOPATHY; NEOPLASM; NEPHROLITHIASIS; NEUROPATHY; PANCREATITIS; PNEUMONIA; PREDICTION; PROGNOSIS; REVIEW; SIDE EFFECT; SURVIVAL; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT; VIRUS RESISTANCE;

ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CRITICAL CARE; HIV INFECTIONS; HUMANS; INTENSIVE CARE UNITS; ITALY;

EID: 38049125977     PISSN: 03759393     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (53)

1. Schein RM, Fischl MA, Pitchenik AE, Sprung CL. ICU survival of patients with the acquired immunodeficiency syndrome. Crit Care Med 1986; 14:1026-7.
2. Layon AJ, D'Amico R. Intensive care for patients with acquired immunodeficiency syndrome-medicine versus ideology, Crit Care Med 1990;18:17-9.
3. Friedman Y, Franklin C. Admission of AIDS patients to a medical intensive care unit: causes and outcomes. Crit Care Med 1990;18:346-7.
4. Smith RL, Levine SM, Lewis ML. Prognosis of patients with AIDS requiring intensive care. Chest 1989;96:857-61.
5. Wachter RM, Luce JM, Lo B, Raffin TA. Life-sustaining treatment for patients with AIDS. Chest 1989;95:647-52.
6. Rogers PL, Lane HC, Henderson DK, Parrillo J, Masur H. Admission of AIDS patients to a medical intensive care unit: causes and outcome. Crit Care Med 1989; 17:113-7.
7. Luce JM, Wachter RM. Intensive care for patients with the acquired immunodeficiency syndrome. Intensive Care Med 1989;15:481-2.
8. Luce JM, Wachter RM, Hopewell PC. Intensive care of patients with the acquired immunodeficiency syndrome: time for a reassessment? Am Rev Respir Dis 1988; 137:1261-3.
9. Deam R, Kimberley AP, Anderson M, Soni N. AIDS in ICUs: outcome. Anesthesia 1988;43:150-1.
10. Huang L, Quartin A, Jones D, Havlir DV. Intensive Care of Patients with HIV Infection. N. Engl J Med 2006;305:173-81.
11. Morris A, Masur H, Huang L. Current issues in critical care of the human immunodeficiency virus-infected patient. Crit Care Med 2006;34:42-9.
12. Lazard T, Retel O, Guidet B, Maury E, Valleron AJ, Offenstadt G. AIDS in a medical intensive care unit: immediate prognosis and long-term survival. JAMA 1996 16;276:1240-5.
13. De Palo VA, Millstein BH, Mayo PH, Salzman SH, Rosen MJ. Outcome of intensive care in patients with HIV infection. Chest 1995;107:506-10.
14. Franklin C, Friedman Y, Wong T, Hu TC. Improving longterm prognosis for survivors of mechanical ventilation in patients with AIDS with PCP and acute respiratory failure. Five-year follow-up of intensive care unit discharges. Arch Intern Med 1995;155:91-5.
15. Curtis JR, Greenberg DL, Hudson LD, Fisher LD, Krone MR, Collier AC. Changing use of intensive care for HIV-infected patients with Pneumocystis carinii pneumonia. Am J Respir Crit Care Med 1994;150:1305-10.
16. Bennett RL, Gilman SC, George L, Guze PA, Bennett CL. Improved outcomes in intensive care units for AiDS-related Pneumocystis carinii pneumonia: 1987-1991. J Acquir Immune Defic Syndr 1993;6:1319-21.
17. Brown J, Sprung CL. Ethical considerations in the treatment of AIDS patients in the intensive care unit. Crit Care Clin 1993;9:115-23.
18. Wachter RM, Luce JM, Turner J, Volberding P, Hopewell PC. Intensive care of patients with the acquired immunodeficiency syndrome. Outcome and changing patterns of utilization. Am Rev Respir Dis 1986;134:891-6.
19. Banks RA, Lindley KJ, Pozniak AL. AIDS: a problem for intensive care. Intensive Care Med 1985;11:169-71.
20. Rosen MJ, De Palo VA. Outcome of intensive care for patients with AIDS. Crit Care Clin 1993;9:107-14.
21. Wachter RM, Luce JM, Hopewell PC. Critical care of patients with AIDS. JAMA 1992;267:541-7.
22. Morris A, Creasman J, Turner J, Luce JM, Wachter RM, Huang L. Intensive care of human immunodeficiency virus-infected patients during the era of highly active antiretroviral therapy. Am J Respir Crit Care Med 2002; 166:262-7.
23. Casalino E, Wolff M, Ravaud P, Choquet C, Bruneel F, Regnier B. Impact of HAART advent on admission patterns and survival in HIV-infected patients admitted to an intensive care unit. AIDS 2004; 18:14-33.
24. Afessa B, Green B. Clinical course, prognostic factors, and outcome prediction for HIV patients in the ICU. The PIP (Pulmonary complications, ICU support, and prognostic factors in hospitalized patients with HIV) study. Chest 2000;118:138-45.
25. Palacios R, Hidalgo A, Reina C, de la Torre M, Marquez M, Santos J. Effect of antiretroviral therapy on admissions of HIV-infected patients to an intensive care unit. HIV Med 2006;7:193-6.
26. Nuesch R, Geigy N, Schaedler E, Battegay M. Effect of highly active antiretroviral therapy on hospitalization characteristics of HIV infected patients. Eur J Clin Microbiol Infect Dis 2002;21:6847.
27. Vincent B, Timsit JF, Auburtin M, Schortgen F, Bouadma L, Wolff M et al. Characteristics and outcomes of HIV-infected patients in the ICU: impact of the highly active antiretroviral treatment era. Intensive Care Med 2004;30:859-66.
28. Khouli H, Afrasiabi A, Shibli M, Hajal R, Barrett CR, Homel P. Outcome of critically ill human immunodeficiency virus-infected patients in the era of highly active antiretroviral therapy. J Intensive Care Med 2005;20:327-33.
29. Department of Health and Human Services. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. (http://www.AIDSinfo.nih.gov.)
30. Festic E, Gajic O, Limper AH, Aksamit TR. Acute respiratory failure due to pneumocystis pneumonia in patients without human immunodeficiency virus infection: outcome and associated features. Chest 2005;128:573-9.
31. Bonarek M, Morlat P, Chene G, Rapin D, Hilbert G, Pillet O et al. Prognostic score of short-term survival in HIV-infected patients admitted to medical intensive care units. Int J STD AIDS. 2001;12:239-44.
32. Leifeld L, Rockstroh J, Skaide S, Wasmuth JC, Altfeld M, Paar WD et al. Indication, outcome and follow up of intensive care in patients with HIV-infection. Eur J Med Res 2000;5:199-202.
33. Rosen MJ. Intensive care of patients with HIV infection. Semin Respir Infect 1999; 14:366-71.
34. Gill JK, Greene L, Miller R, Pozniak A, Cartledge J, Fisher M et al. ICU admission in patients infected with the human immunodeficiency virus a multicentre survey. Anesthesia 1999;54:727-32.
35. Curtis JR, Bennett CL, Horner RD, Rubenfeld GD, DeHovitz JA, Weinstein RA. Variations in intensive care unit utilization for patients with human immunodeficiency virus-related neumocystis carinii pneumonia: importance of hospital characteristics and geographic location. Crit Care Med 1998;26:668-75.
36. Casalino E, Mendoza-Sassi G, Wolff M, Bedos JP, Gaudebout C, Regnier B et al. Predictors of short- and long-term survival in HIV-infected patients admitted to the ICU. Chest 1998;113:421-9.
37. Petrosillo N, Nicastri E, Viale P. Nosocomial pulmonary infections in HIV-positive patients. Curr Opin Pulm Med 2005;11:231-5.
38. Franzetti F, Grassini A, Piazza M, Degl'innocenti M, Bandera A, Gazzola L et al. Nosocomial bacterial pneumonia in HIV-infected patients: risk factors for adverse outcome and implications for rational empiric antibiotic therapy. Infection 2006;34:9-16.
39. Rosen MJ, Clayton K, Schneider RF, Fulkerson W, Rao AV, Stansell J et al. Intensive care of patients with HIV infection: utilization, critical illnesses, and outcomes. Pulmonary Complications of HIV Infection Study Group. Am J Respir Crit Care Med 1997;155:67-71.
40. Nunez M, Soriano V. Management of patients co-infected with hepatitis B virus and HIV. Lancet Infect Dis 2005;5:374-82.
41. Friis-Moller N, Weber R, Reiss P, Thiebaut R, Kirk O, d'Arminio Monforte A et al. DAD study group. Cardiovascular disease risk factors in HIV patients Association with antiretroviral therapy. Results from the DAD study. AIDS 2003;17:1179-93.
42. Lawn SD, Bekker LG, Miller RF. Immune reconstitution disease associated with mycobacterial infections in HIV infected individuals receiving antiretrovirals. Lancet Infect Dis 2005;5:361-73.
43. Hirsch HH, Kaufmann G, Sendi P, Battegay M. Immune reconstitution in HIV infected patients. Clin Infect Dis 2004;38:1159-66.
44. Shelburne SA 3rd, Hamill RJ, Rodriguez-Barradas MC, Greenberg SB, Atmar ILL, Musher DW et al. Immune reconstitution inflammatory syndrome: Emergence of a unique syndrome during highly active antiretroviral therapy. Medicine (Baltimore) 2002;81:213-27.
45. Friis-Moller N, Sabin CA, Weber R, d'Arminio Monforte A, El-Sadr WM, Reiss P et al. Data Collection on adverse events of anti-hiv drugs (DAD) study group. Combination anti-retroviral therapy and the risk of myocardial infarction. N Engl J Med 2003;349:1993-2003.
46. Aberg JA, Gallant JE, Anderson J, Oleske JM, Libman H, Currier JS et al. HIV Medicine Association of the Infectious Diseases Society of America. Primary care guidelines for the management of persons infected with human immunodeficiency virus: recommendations of the HIV Medicine Association of the Infectious Diseases Society of America. Clin Infect Dis 2004;39:609-29.
47. Morris A, Wachter RM, Luce J, Turner J, Huang L. Improved survival with highly active antiretroviral therapy in HIV-infected patients with severe Pneumocystis carinii pneumonia. AIDS 2003; 17:73-80.
48. Aceti A, Pasquazzi C, Zechini B, De Bac C; LIVERHAART Group. Hepatotoxicity development during antiretroviral therapy containing protease inhibitors in patients with HIV: The role of hepatitis B and C virus infection. J Acquir Immune Defic Syndr 2002;29:41-8.
49. Chattha G, Arieff AI, Cummings C, Tierney LM Jr. Lactic acidosis complicating the acquired immunodeficiency syndrome. Ann Intern Med 1993;118:37-9.
50. Miller KD, Cameron M, Wood LV, Dalakas MC, Kovacs JA. Lactic acidosis and hepatic steatosis associated with use of stavudine: Report of four cases. Ann Intern Med 2000;133: 192-6.
51. Bonnet F, Bonarek M, Morlat P, Mercie P, Dupon M, Gemain MC et al. Risk factors for lactic acidosis in HIV-infected patients treated with nucleoside reversetranscriptase inhibitors: A case-control study. Clin Infect Dis 2003;36:1324-8.
52. Claessens YE, Cariou A, Monchi M, Soufir L, Azoulay E, Rouges P et al. Detecting life-threatening lactic acidosis related to nucleoside-analog treatment of human immunodeficiency virus-infected patients, and treatment with L-carnitine. Crit Care Med 2003;31:1042-7.
53. Fouty B, Frerman F, Reves R. Riboflavin to treat nucleoside analogue-induced lactic acidosis. Lancet 1998;302:1-2.